MedPath
NMPA Approval

Telavancin Hydrochloride for Injection

国药准字HJ20250017

February 11, 2025

Drug Information

注射用盐酸替拉凡星

注射剂

0.75g(按C₈₀H₁₀₆Cl₂N₁₁O₂₇P计)

化学药品

February 11, 2025

February 10, 2030

Company Information

Applicant Company

1600 West End Avenue, Suite 1300, Nashville, TN 37203 United States of America

Manufacturing Company

300, Songdo bio-daero,Yeonsu-gu, Incheon, Incheon 21987 KOREA, SOUTH

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

注射用盐酸替拉凡星 - NMPA 批准文号 | MedPath